The Emerging Role of Phosphodiesterases in Movement Disorders

Abstract

A BS TRACT: Cyclic nucleotide phosphodiesterase (PDE) enzymes catalyze the hydrolysis and inactivation of the cyclic nucleotides cyclic adenosine monophosphate and cyclic guanosine monophosphate, which act as intracellular second messengers for many signal transduction pathways in the central nervous system. Several classes of PDE enzymes with specific tissue distributions and cyclic nucleotide selectivity are highly expressed in brain regions involved in cognitive and motor functions, which are known to be implicated in neurodegenerative diseases, such as Parkinson's disease and Huntington's disease. The indication that PDEs are intimately involved in the pathophysiology of different movement disorders further stems from recent discoveries that mutations in genes encoding different PDEs, including PDE2A, PDE8B, and PDE10A, are responsible for rare forms of monogenic parkinsonism and chorea. We here aim to provide a translational overview of the preclinical and clinical data on PDEs, the role of which is emerging in the field of movement disorders, offering a novel venue for a better understanding of their pathophysiology. Modulating cyclic nucleotide signaling, by either acting on their synthesis or on their degradation, represents a promising area for development of novel therapeutic approaches. The study of PDE mutations linked to monogenic movement disorders offers the opportunity of better understanding the role of PDEs in disease pathogenesis, a necessary step to successfully benefit the treatment of both hyperkinetic and hypokinetic movement disorders.

Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson’s Disease: A Nationwide Cohort Study

“…Research on novel therapies to slow the neurodegenerative progression or to prevent PD in the early stages has been conducted ( Kalia et al, 2015 ). Specifically, a number of studies have suggested various medications including statins ( Kumar et al, 2012 ; Kang et al, 2017 ), phosphodiesterase inhibitors ( Nthenge-Ngumbau and Mohanakumar, 2018 ; Erro et al, 2021 ), and renin-angiotensin system (RAS) inhibitors ( Ana Flavia et al, 2017 ; Victor Teatini Ribeiro, 2020 ) as drug repurposing candidates with demonstrated neuroprotective effects.…”

Single cell analysis of gene expression in the substantia nigra pars compacta of a pesticide-induced mouse model of Parkinson’s disease

“…Pathways were enriched in terms relevant to PD, such as GABAergic synapse pathway, dopaminergic synapse and cholinergic synapse (adjusted P < 9.4 × 10 −4 ). Relevant genes included Prkacb, Fos, Adcy5 and Homer1 (Erro et al, 2021; Odumpatta and Arumugam, 2021; Tran et al, 2020; Zhu et al, 2018).…”

Motor, epileptic, and developmental phenotypes in genetic disorders affecting G protein coupled receptors-cAMP signaling

“…Specifically, cAMP levels finely regulate the activity of protein such as the cAMP-regulated phosphoprotein molecular mass 32 (DARPP-32) and the cAMP-response element-binding protein (CREB). These proteins are thought to play an important role by mediating the dopaminergic neuromodulatory effects on GABAergic transmission and regulating the long-term synaptic plasticity and neuronal growth at MSNs level ( 62 ). Thus, through an altered basal ganglia activity, altered cAMP levels may underpin movement disorders such as dystonia, chorea, and parkinsonism.…”